

Manufacturing Brighter Futures

May 29, 2024





Enable
widespread
patient access
to life-saving
cell and gene
therapies



//

The **status quo** in cell and gene therapy for most patients today **represents death or serious disability**

//



Tim Hunt

Chief Executive Officer,
Alliance for Regenerative Medicine (ARM)


Globally, less than 4% of patients who could benefit from approved CAR-T therapies have been able to access them

900K*

Addressable Patient
Population

~28K


Total CAR-T
patients treated




*Projected : Includes ALL, DLBCL, Multiple Myeloma, CLL and FL. Source: McKinsey, Statnews.
Source: Ori Biotech Internal Research at www.oriotech.com

Small molecules and biologics

If we develop **safe and effective products**,
we assume they will be
commercially viable





Cell and gene therapy

Developing **safe and effective** products is **not enough** to ensure that cell and gene therapies will be **viable**

//

Cell and gene (developers) are essentially manufacturing companies... You have to prioritize that first in addition to clinical and research

//



Andrew Obenshain

Chief Executive Officer, Bluebird Bio
ARM State of the Union 2024

Today's Therapy Development Cycle



~1998 Products



Fundraising
or Partner?



~1812 Products

Today's Therapy Development Cycle




Today's Therapy Development Cycle



Today's Therapy Development Cycle



Today's Therapy Development Cycle



Data shown above is from Beacon (Hanson Wade Database), ARM, and FDA

Success



TBD



And many others...

Who is Ori**bi**otech

Partnered

with leading Large Pharma,
Biotech, Academic Medical
Research, and CDMOs

Labs in

Philadelphia, London and
Cambridge (UK) – More
coming soon!

83 Person Team

CGT CDMO, Therapy
Developer, Large Pharma,
Technology, and
Engineering Experience

Founded in 2015


Mission to enable
widespread patient
access to CGT

Team with 100+ Years

operational experience



Over the past 5 years,
we have been working
to develop a platform
that is...



to support you and
the other heroes of
cell therapy.




Oribiotech

hello

iro




Ori Platform Technology: Bioreactor, LVC, SVC, and OriConnect™



What If I Told You That IRO Will...



Automate Better Biology™





- ✔ Supports different cell suspension culture types and workflows
- ✔ Allows for activation, transduction, expansion, and harvest in one platform
- ✔ Begin with ~50M cells (at 50ml) and yield ~12B cells (at 1L)
- ✔ Reduces manufacturing process times by 25% (average of 1-2 days)
- ✔ Achieves higher cell yields and transduction efficiencies than the “gold standard”
- ✔ Delivers cells with >95% viability and potent cancer killing activity
- ✔ (Delivers) 170x fold expansion with no signs of exhaustion
- ✔ Delivers target cell yield with a 50% reduction in MOI

What If I Told You That IRO Will...



Accelerate Product Development





- ✓ Enables a seamless transition from R&D into the clinic and from the clinic to commercial scale manufacturing
- ✓ Eliminates the need for comparability during scale up, shaving years off drug development
- ✓ Brings products to market faster by reducing process development and tech transfer time
- ✓ Helps you reach your next value inflection point more quickly
- ✓ Empowers your scientists, offering them the freedom to optimize and the flexibility to innovate
- ✓ Puts control back in the hands of your expert scientists via customizable software
- ✓ Reduces batch failure rates to hit target dose more consistently
- ✓ Enables complete product traceability via our digital, cloud native platform



What If I Told You That IRO Will...



Scale Your Impact™




- ✓ Increases throughput to ~1,000 doses per year in 1,000 sq ft
- ✓ Reduces labor costs by more than 50%
- ✓ Enables manufacturing in less expensive, lower grade clean rooms
- ✓ Designed to support full robotic automation and advanced analytics (AI, ML)
- ✓ Unlocks multi-site manufacturing capability
- ✓ Reduces manufacturing costs by 30-50%
- ✓ Delivers a > 50% reduction in manufacturing facility footprint
- ✓ Integrates with industry leading software (e.g. EBMR, ELN, SCADA etc.) via APIs


What If I Told You That IRO Will...



Automate Better Biology



Accelerate Product Development



Scale Your Impact



I bet you probably wouldn't
believe me...

Completed Platform Validation

> 500
Runs

Characterization runs completed (in house and at partner sites in NA and UK)

> 40
Donors
/ Patients

Testing platform's ability to address donor and patient variability, showcasing the robustness of system outputs across different starting material

10
Unique
Processes

Different processes including CAR-T, TCR-T, TILs, CD34+, with CAR-M and others on the horizon

10
Partners

5 therapy developers, 4 CDMOs, and 1 AMC



//

I expected automation,
I expected more process insights,
but I never expected better
biological performance right out of
the gate

//



Jason Bock

Co-Founder and Chief Executive Officer,
CTMC – A Joint Venture Between
Resilience + MD Anderson Cancer Center

Let's Manufacture
Brighter Futures
Together.



Jason C. Foster

Chief Executive Officer

jason.foster@oribiotech.com

M: +447920278334



Thomas Heathman, PhD

Chief Commercial Officer

thomas.heathman@oribiotech.com

M: +1 (201) 962-6447



Kale Feeter

Director, Business Development

kale.feeter@oribiotech.com

M: +1 (707) 718-6129



Marianna Mavropoulou

Business Development Executive

marianna.mavropoulou@oribiotech.com

M: +447771197035

oribiotech

